Project description
New device prevents sudden cardiac death
Sudden cardiac death (SCD) represents a major public health concern since it is responsible for about 20 % of all deaths in Europe. It affects mostly patients with myocardial infarction (MI) precedents. SCD can be prevented with the implantable cardioverter-defibrillator (ICD) device. However, it is costly and associated with potentially serious complications. The ICD is recommended as a prophylactic solution for post-MI patients, but only a few of them receive the device, while the majority of implantations are directed to patients without a medical recommendation for it. The EU-funded PROFID project will use clinical datasets and advanced technology to develop a clinical decision support instrument that will predict the individual SCD risk and identify post-MI patients suitable for an ICD device.
Objective
Sudden cardiac death (SCD) is a major public health problem accounting for ~20% of all deaths in Europe with an estimated yearly incidence of ~350-700,000, often in patients with previous myocardial infarction (MI). In SCD, the heart suddenly and unexpectedly stops beating. If untreated, the patient dies within minutes, but SCD can be successfully prevented by an implantable cardioverter-defibrillator (ICD). The ICD is highly effective, but is associated with potentially severe complications and high healthcare costs. Based on historical evidence, guidelines recommend prophylactic ICD implantation in post-MI patients with left ventricular ejection fraction (LVEF)≤35% to prevent SCD. However, only a minority of these patients will ever need the device. In addition, in absolute numbers the majority of SCD cases occurs in patients with LVEF>35% who are currently not considered for prophylactic ICD. Due to the inherent risks and considerable health care expenditures, a personalised treatment approach for ICD implantation is urgently required. Using state-of-the-art methods and large clinical datasets from established international cohorts and registries across different European geographies, PROFID will develop a clinical decision support tool (risk score) to predict the individual SCD risk and identify those post-MI patients that will optimally benefit from an ICD. Two parallel randomised clinical trials will validate implementation of the risk score to determine ICD implantation, while health economic analyses will assess its economic impact on health care systems. A software tool for clinical use of the risk score will be implemented, and a pilot run in 3 European regions with participation of insurance companies and authorities. The unique composition of the consortium with key opinion leaders, patient organisations, large hospital chains, payers, policy makers and state authorities across Europe, will ensure implementation into routine clinical practice.
Fields of science
Programme(s)
Topic(s)
Funding Scheme
IA - Innovation actionCoordinator
10117 Berlin
Germany
See on map
Participants (26)
1081 HV Amsterdam
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
3511 EP UTRECHT
See on map
M13 9PL Manchester
See on map
80335 Munchen
See on map
YO10 5DD York North Yorkshire
See on map
42285 Wuppertal
See on map
28010 Madrid
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
28010 Madrid
See on map
06903 Biot Sophia Antipolis
See on map
60323 FRANKFURT AM MAIN
See on map
31076 Toulouse Cedex 3
See on map
B4 7ET Birmingham
See on map
40 055 Katowice
See on map
8000 Aarhus C
See on map
104 22 Stockholm
See on map
31096 Haifa
See on map
1085 Budapest
See on map
779 00 Olomouc
See on map
LS2 9JT Leeds
See on map
20145 Milano
See on map
95447 Bayreuth
See on map
Participation ended
1114 AB Amsterdam-Duivendrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
8200 Aarhus
See on map
28040 Madrid
See on map
13125 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
04289 Leipzig
See on map